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INTRODUCTION
p63 is a member of the p53 tumor-suppressor gene family
with structural homology to p53, but one that, from a func-
tional point of view, shows both similarities and differences
from p53 (1-5). In fact, the p63 gene transcript undergoes
multiple alternative splicing and, in addition, can be tran-
scribed from two different promoters, resulting in the gen-
eration of a variety of p63 isoforms, including three transac-
tivating (TA-p63,  - - ) and three amino terminal-trun-
cated proteins ( N-p63,  - - ) (1, 2, 5). Interestingly, these
different molecular species can exert contrasting effects on
the same molecular targets, interfering with p53 functions.
TA-p63 molecules (especially TA-p63 ) have functions similar
to p53 in inducing cell-cycle arrest and apoptosis. However,
N-p63 isoforms (especially the  N-p63 isoform) act as
a dominant-negative factor, inhibiting transcription activa-
tion by both p53 and TA-p63 isoforms (1, 2, 6). When abnor-
mally over-expressed as a result of gene amplification, these
latter p63 isoforms are thought to behave as oncogenic mo-
lecules (1, 5, 7-9).
Recently, p63 has been proposed to be a specific marker of
precursor/stem cells in many epithelial tissues and to repre-
sent a candidate marker for exploring thymic stem cells (5,
10-12). The fine-tuning of different p63 isoforms in the basal
and differentiating compartments is necessary to maintain
the regenerative quality of epithelial stem cells, as well as the
regulation of epidermal mesenchyme interactions, replicative
senescence, and angiogenesis (13-15). Therefore p63 is essen-
tial during embryonic life for the correct development of limb
craniofacial, epithelial differentiation and proliferation rather
than tumor suppression (16). However, the final designation
of p63 as an oncogene or a tumor suppressor gene is still under
debate (6). In contrast, p53 is a well-known tumor suppressor
gene located on chromosome 17p13.1 and encoding a nuclear
phosphoprotein of 53 kDa (17). It is believed to induce cell
cycle arrest in the presence of damaged DNA, finally leading
cells to apoptosis. Regarding malignant lymphomas (MLs),
p53 overexpression has been found in 33.3% (18) and 41.9%
(19) of cases and has been related to disease-specific survival
(18). Recently, alterations and loss of p63 expression in ad-
vanced stages of human bladder carcinoma have been described
(20-22) but their clinical significance still has to be defined.
Information regarding p63 expression in malignant lymphoma
(ML) is scanty, and few data are available regarding ML. Start-
ing from these grounds, we have investigated the expression
of p63 in reactive hyperplasias (RHs) and in a series of MLs
using immunohistochemistry.
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Expression of p63 in Reactive Hyperplasias and Malignant Lymphomas
p63 is a recently described p53 homologue. It is involved in survival and differenti-
ation of reserve/stem cells in epithelia. To obtain new insights into the role of p63
in malignant lymphomas (MLs), immunohistochemical staining for p63 and p53 was
performed in 126 cases of MLs. p63 was expressed in 38 cases of MLs (30.2%)
including 32/61 cases (52.5%) of diffuse large B-cell lymphoma (DLBCL), 1/8 cases
(12.5%) of precursor T-lymphoblastic lymphoma (T-LBL), 4/14 cases (28.6%) of
follicular lymphoma, 1/6 cases (16.7%) of T/NK cell lymphoma. Among p63 positive
cases, p63 was strongly expressed in 15/32 cases of DLBCL and 1/1 case of T-LBL.
p63 was not expressed in mantle cell lymphomas, peripheral T-cell lymphomas,
marginal zone B-cell lymphomas, plasma cell myelomas and Hodgkin’s lymphomas.
p63 was coexpressed with p53 in 18/38 p63 positive cases in which only 4 cases
were strongly coexpressed. All p63+/p53+ cases were DLBCL. p63 overexpression
(above 30%) cases showed significant poor survival (p=0.0228) in DLBCL. However,
there was no statistically significant correlation between p63 expression and IPI score
on Multivariate analysis. We could speculate that p63 could act indirectly as an onco-
gene by inhibiting p53 functions. Stage of differentiation of neoplastic lymphocytes
appears to have a correlation with p63 expression in MLs.
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MATERIALS AND METHODS
Study population
The study group consisted of 10 RHs and 126 previously
untreated MLs, classified according to World Health Orga-
nization (WHO) criteria (23). All tissue samples were fixed
in 10% formalin and paraffin embedded following routine
procedures. The ML series included: 61 diffuse large B-cell
lymphoma (DLBCL), 14 follicular lymphoma (FL), 22 periph-
eral T-cell lymphoma (PTCL), 8 precursor T-lymphoblastic
lymphoma (T-LBL), 6 T/NK cell lymphoma (T/NKL), 3
mantle cell lymphoma (MCL), 3 Burkitt’s lymphoma (BL),
5 Hodgkin’s lymphoma (HL), 2 marginal zone B-cell lym-
phoma (MZBCL), 1 primary mediastinal large B-cell lym-
phoma (PMLBCL), 1 plasmacytoma. Control tissues includ-
ed tonsil obtained from children during tonsillectomy. Tis-
sue microarray (TMA) blocks were created from 72 cases of
MLs and 10 cases of RHs.
Immunohistochemical staining and antibodies
The antibody panel for characterizing lymphomas includ-
ed CD20 (clone L26; Dako, Glostrup, Denmark), CD3 (clone
PS1; Novocastra, Newcastle, U.K.), CD45RO (Immunotech,
Marseille, France), terminal-deoxynucleotidyl transferase
(TdT, rabbit antibody; Dako), CD56 (Dako), CD5 (clone
4C7; Novocastra), CD10 (Dako), cyclin D1 (Novocastra),
bcl2 (Dako), CD15 (Immunotech) and CD30 (Dako). For
the TMA, hematoxylin and eosin-stained sections from each
paraffin-embedded, formalin-fixed block were used to define
diagnostic areas, and 2 to 5 (average 4) random, representa-
tive 0.6-mm cores were obtained from each case and insert-
ed in a grid pattern into a recipient paraffin block using a
tissue arrayer (Beecher Instruments, Silver Spring, MD,
U.S.A.). Sections (5  m) were cut from each TMA and paraf-
fin blocks and mounted on adhesive-treated glass slides, rehy-
drated and treated for antigen retrieval (0.01 M, citrate buffer,
pH 6.5, microwaved three times at 750 W for 10 min, and
once for 10 min at 600 W). Immunostaining was performed
using the avidin-streptavidin-peroxidase technique (Biogenex,
San-Ramon, CA, U.S.A.). Consecutive sections were analyzed
using p63, p53 and Ki-67 specific antibodies. Anti-p63 (Ab-
1, Oncogene Research Products, Boston, MA, U.S.A.), is a
mouse monoclonal antibody (clone-4A4) corresponding to a
region (amino acids 1-205 of  N-p63 isoforms) common
to six isoforms of the p63 molecule. The p53 antibody (Novo-
castra) is a DO-7 monoclonal antibody, which specifically
detects human wild type and mutant p53. The MIB-1 anti-
body (Biogenex) is produced by immunized mice against
recombinant Ki-67 gene products. The slides were counter-
stained with hematoxylin.
Evaluation of immunohistochemical results
Only nuclear staining above 5% was interpreted as posi-
tive for p63 and p53 expression. Immunostaining results for
p63, p53, and Ki-67 were semiquantitatively evaluated accord-
ing to the percentage of positive tumor cells in each case. Stain-
ing intensity was graded as + (weak), ++ (moderate), and
+++ (strong).
Statistical analysis
The Kaplan-Meier method was used to estimate overall
survival distributions. DLBCL cases with p63 and p53 over-
expression above 30% were included on survival analysis.
Overall survival was calculated as the time from diagnosis
to the date of death or last contact. Patients who were alive
at last contact were treated as censored for overall survival
analysis. The log-rank test was used to compare the clinical
characteristics between the subgroups. Univariate and mul-
tivariate analysis was performed using the Cox regression
method. Stepwise selection was used to determine the vari-
ables that were independent predictors of overall survival.
SPSS 11.0 Statistical soft ware (U.S.A.) program was used for
the data analysis.
RESULTS
Control tissues
Nuclear p63 expression was confined to basal components
of squamous epithelium in tonsil. A few scattered p63 immu-
noreactive nuclei were observed within germinal centers. p53
and Ki-67 were randomly positive in nuclei of basal cells. The
basal cells did not coexpress p63 and p53.
Reactive hyperplasias
There was 3 Castleman’s disease, 1 progressive transfor-
mation of germinal centers, and 6 reactive follicular hyper-
plasias. p63 and p53 were not expressed in RHs (10 cases).
Ki-67 was strongly positive for activated germinal center cells
and usually negative for parafollicular small lymphocytes.
Hodgkin' 's lymphomas
There were 4 cases of mixed cellularity and 1 nodular scle-
rosis of HL. p63 was not expressed in 5 cases of HL. p53 was
strongly expressed in Reed-Sternberg cells and its variants.
p53 was not expressed in background lymphoid cells.
Malignant lymphomas
p63 was expressed in 38 cases of MLs studied (30.2%) in-754 C.-K. Park, Y.-H. Oh
cluding 32/61 cases (52.5%) of DLBCL, 1/8 cases (12.5%)
of T-LBL, 4/14 cases (28.6%) of FL, 1/6 cases (16.7%) of
T/NKL. Among p63 positive cases, p63 was diffusely and
strongly expressed in 15/32 cases (46.9%) of DLBCL (Fig. 1)
and 1/1 case of T-LBL (Fig. 2) when using 30% as cut off
value. Remaining cases were focally and weakly expressed.
p63 was not expressed in MCL (3 cases), PTCL (22cases),
MZBCL (2 cases), plasmacytoma (1 case) and HL (5 cases).
CD10 was expressed in 10/52 cases (19.2%) of DLBCL
when using 30% as cut off value. Among 10 cases of CD10
expression, p63 was detected in only one case (1/10, 10%).
In contrast, p63 was expressed in 12/42 cases (28.6%) of
Fig. 2. Histologic findings of a case of precursor T-lymphoblastic lymphoma (T-LBL) developing in a 15-yr-old boy (A). p63 is diffusely and
strongly positive (B). In contrast, p53 is negative (C).
A B C
Fig. 1. Histologic findings of a case of diffuse large B-cell lymphoma (DLBCL) (H&E stain, ×400) (A). The tumor cells show high Ki-67 index
(B) and strong p63 expression (C) devoid of p53 expression (D).
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95% confidence
interval for RR
Variable
No. of
cases
p RR
Upper
bound
Lower
bound
Age >60 yr (vs. <60 yr) 17/47 0.001 5.120 1.903 13.779
LDH >200 (vs. <200) 8/23 0.216 0.025 0.000 8.697
Stage III/IV (vs. I/II) 14/26 1.000 1.000 0.341 2.932
Performance >70% 11/29 0.575 0.701 0.202 2.429
(vs. <70%)
Extranodal extension (vs. no) 2/35 0.648 1.612 0.207 12.523
Low IPI (vs. High IPI) 23/12 0.123 0.434 0.150 1.255
p63+>30% (vs. <30%) 8/40 0.032 2.888 1.093 7.632
p53+>30% (vs. <30%) 8/39 0.450 1.529 0.508 4.604
Table 1. Results of univariate Cox proportional hazards regression
analysis
RR, relative risk; IPI, International Prognostic Index.
95% confidence
interval for RR
Variable
No. of
cases
p RR
Upper
bound
Lower
bound
Age >60 yr (vs. <60 yr) 9/19 0.053 6.680 0.974 45.807
Low IPI (vs. High IPI) 9/19 0.225 2.003 0.363 11.048
p63+>30% (vs. <30%) 3/25 0.716 1.474 0.182 11.949
Table 2. Results of multivariate Cox proportional hazards regres-
sion analysis 
RR, relative risk; IPI, International Prognostic Index.Expression of p63 in Reactive Hyperplasias and Malignant Lymphomas 755
CD10 negative DLBCL.
Using an arbitrary threshold of 5% positive staining, expres-
sion of p53 was detected in 50 of 119 cases (38.8%).
p53 was expressed in 27/60 DLBCL (45%), 2/8 T-LBL
(25%), 8/21 PTCL (38.1%), 4/6 T/NKL (66.7%), 3/3 BL
(100%), 1/13 FL (7.7%), 0/1 MZBCL (0%). There were signif-
icant correlations between p53 immunoreactivity and histo-
logic subtypes of MLs. Diffuse strong positive immunoreac-
tivity was the most constant finding in high grade MLs. Low
grade lymphomas were p53 negative.
The relationship between p63 and p53 expression in
malignant lymphomas
Among the 38 cases positive for p63, 14 cases coexpressed
p53 (36.8%) when using 5% as cut off value. When using
30% as cut off value, 4/38 p63 positive cases (10.5%) coex-
pressed p53 strongly and diffusely. They were all DLBCL cases.
Immunohistochemical staining results, IPI scores, and
their effect on survival
Univariate Cox proportional hazards regression analysis
was performed according to following variables such as age,
LDH, stage, patient’s performance, extranodal extension, p63
and p53 positivity status, which are shown in Table 1. Age
was the most significant factor followed by high p63 positivity.
Other variables were not significant. Finally, multivariate Cox
proportional hazards regression analysis according to signifi-
cant variable was used (Table 2). Age was significant but there
was no significance between international prognostic index
and p63 expression.
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Fig. 3. Kaplan-Meier survival analysis in DLBCL according to p63 (A) and p53 expression (B). Cases with p63 overexpression above 30%
show significantly poor survival regardless of p53 expression. On the other hand, cases with p53 overexpression above 30% show no sig-
nificance on survival.
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Fig. 4. Survival analysis of DLBCL cases with p63 overexpression above 30% according to p53 expression. In p53 negative group (less
than 30%), cases with p63 overexpression above 30% show significant poor survival (A) but p53 positive group (more than 30%) is too small
in number (B).
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Survival analysis was performed in 48 patients with a medi-
an observation period of 27 months. Cases with p63 overex-
pression above 30% showed significantly poor survival regard-
less of p53 expression (Fig. 3). On the other hand, p53 had
no significance on survival analysis (Fig. 3). Survival analysis
was also performed by dividing the study group with respect
to p53. p53 negative cases were 48 and p53 positive cases
were 8 in number. In p53 negative group, p63 positive cases
had significantly poor survival but p53 positive group was
too small in number (Fig. 4).
DISCUSSION
To our knowledge, this is the first study to analyze the
immunoreactivity of p63 and p53 in a large number of ML
specimens and to correlate p63 and p53 immunoreactivity
with clinical follow-up. More recently, MLs were described
as p63 immunoreactive in a survey study on human tumors
(23), but relationship between p63 and p53 immunostain-
ing in respect to patient’s prognosis with ML has not yet been
reported. Di Como et al. (24) examined p63 expression pro-
files in a number of non-Hodgkin’s B-cell lymphomas, includ-
ing those classified as CLL/SLL, FL, DLBCL, anaplastic large-
cell lymphoma, MCL, and MZBCL. They observed diffuse
to intense staining in DLBCL and FL (24). Furthermore, in
FL, the strongest staining was observed in grade 3 cases in
the larger neoplastic cells. Higher levels of p63 protein expres-
sion were found in tumor lymphocytes compared with normal
lymphoid tissues by RT-PCR (24). Chilosi et al. (25) reported
that T-cell precursor lymphomas did not express p63, whereas
7 of 8 cases of PMLBCL expressed TA-p63 . But details on
ML subtypes and discussions on the significance of p63 over-
expression in MLs were not provided (25). In humans, het-
erozygous germline p63 mutations have been described in
EEC syndrome, in which a single case has been described
with thymic hypoplasia (26) although no lymphoid or thymic
abnormalities have been described in p63-null mice (16, 27).
There is also another case study examined a sporadic incident
of EEC syndrome (ectrodactyly ectodermal dysplasia-clefting
syndrome) of complete form of the anomaly with late onset
of non-Hodgkin’s lymphoma (28). Interestingly, the non-
Hodgkin’s lymphoma was of the diffuse large-cell type, where
we observed intense p63 immunoreactivity. Our results of
study are consistent with those of previous studies (24, 28).
In this study p63 was expressed in 38 cases of MLs studied
(30.2%) including 32/61 cases (52.5%) of DLBCL, 1/8 cases
(12.5%) of T-LBL, 4/14 cases (28.6%) of FL, 1/6 cases (16.7%)
of T/NKL. Among p63 positive cases, p63 was diffusely and
strongly expressed in 15/32 cases of DLBCL and 1/1 case of
T-LBL. Remaining cases were focally and weakly expressed.
p63 was not expressed in MCL, PTCL, MZBCL, plasmacy-
toma and HL. p63 and p53 were not expressed in RHs.
Recently, DLBCL tends to be divided according to CD10
immunoreactivity. So, we also analyzed p63 expression accor-
ding to CD10 immunoreactivity in 52 DLBCL cases. In the
present study, CD10 was expressed in 10/52 cases (19.2%)
of DLBCL. Among 10 cases of CD10 expression, p63 was
detected in only one case (1/10, 10%). In contrast, p63 was
expressed in 12/42 cases (28.6%) of CD10 negative DLBCL.
Although there is no statistical significance between p63 and
CD10 expression, p63 showed a tendency to increase its ex-
pression in CD10 negative DLBCL comparing with in CD10
positive DLBCL.
There are no clear explanations why p63 is overexpressed
in DLBCL. Yang et al. (1) speculated that because p63 lies
close to the translocation break point found in some DLB-
CLs, genomic instability in this area may lead to the dysreg-
ulation of p63. However, this does not explain why TA iso-
forms are predominant in the small group of MLs by use of
RT-PCR (24).
In contrast to p53, a protypical tumor suppressor gene,
somatic mutations of the TP 63 gene are very rare, whereas
germline mutations in TP 63 have been reported for patients
with limb mammary syndrome, split-hand/split-foot malfor-
mation, ankyloblepharon-ectodermal dysplasia-clefting syn-
drome, and EEC syndrome (29-32). Therefore, it might be
that alterations of TP 63 are epigenetic in nature. A number
of studies have investigated the role of p63 in neoplastic trans-
formation and tumor progression including squamous cell
carcinomas (SCCs) of different organs (7, 8, 33, 34), invasive
ductal carcinomas of the breast (35), transitional cell carcino-
mas (6, 36), and thymomas (25). SCCs from different organs
express high levels of  N-p63 (7, 8, 34). The p63 gene may
be the target of 3q27-29 gains common in SCC (1, 8). 
In this context, we might speculate that when certain p63
isoforms are expressed, such as dominant-negative  N-p63,
they could bind to and inhibit transactivation by p53 and
TA-p63 (1). Alternatively, these  N-p63 isoforms, by bind-
ing to specific promoter elements, could block the transcrip-
tion of otherwise critical genes, such as those involved in the
apoptotic response. Rather than inactivating tumor suppressor
activities (e.g., p53), altered patterns of p63 expression could
be driving the transcription of oncogenic proteins, such as
hMDM2, a target reported for TA-p63 (37, 38). Further
studies, integrating mechanistic approaches, are needed to
elucidate the role of p63 in human cancer.
Regarding the prognostic importance of p63 expression in
various types of human carcinomas, the results are contro-
versible. Some authors reported an inverse correlation between
p63 overexpression and advanced tumor stage and poor prog-
nosis (6, 36). In thymomas, p63 expression was not correlat-
ed with clinical aggressiveness (24, 25) although others have
reported a correlation between p53 expression and malignancy
in thymomas. In this study, p63 expression appears to be
related to poor survival in DLBCL. However, as shown in
previous study (36), multivariate analysis failed to prove either
p53 or p63 as an independent prognostic parameter in thisExpression of p63 in Reactive Hyperplasias and Malignant Lymphomas 757
study. Age was the only stastically significant independent
prognostic factor. 
In conclusion, p63 was overexpressed in specific histologic
types of MLs such as T-LBL and DLBCL. In FL, p63 was
weakly expressed in small numbers. The number of cells con-
taining p63 and their distribution tend to depend on the
degree of differentiation of lymphocytes. p63 was rarely coex-
pressed with p53. p63 expression appears to be related to
poor survival although it was not stastically significant on
multivariate analysis. Therefore, we could speculate that p63
could act indirectly as an oncogene by inhibiting p53 func-
tions. Stage of differentiation of neoplastic lymphocytes appears
to have correlation with p63 expression in MLs. Molecular
study regarding different p63 isoform expression and p63
mutation could contribute to understanding the heterogene-
ity of DLBCL and progression of ML.
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